Press Releases

May 16, 2024
Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced today several changes to its executive leadership team.
March 12, 2024
Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced expansion of its leadership team with three key industry veterans: Jason Burdette joining as Senior Vice President, CMC and Technical Operations: Armand Girard as Chief Business Officer; and Tamra Adams, and Chief Financial Officer. These appointments come as the Company expands its remit from pure R&D to encompass support of commercialization.
February 23, 2024
Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination antibiotic under review as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis caused by susceptible gram-negative microorganisms.

In the News

November 11, 2023
Contagion Live
Ahead of its potential approval, the company announced this week it was partnering with Parsippany, NJ-based Melinta Therapeutics in a licensing agreement to commercialize cefepime-taniborbactam.
September 1, 2023
LifeSciencesPA
Chris Burns, PhD, President & CEO of Venatorx, joins the podcast and discusses the importance of having confidence in life and leadership. Chris describes his personal journey fighting against external hurdles, the affect psychology has on all aspects of business and his passion for bridging the intersection of science and business.
October 27, 2022
Contagion Live
Venatorx Pharmaceuticals announced successful phase 3 trial results for cefepime-taniborbactam, its investigational antibiotic aimed at treating complicated urinary tract infections.